16 July 2009
Nancy Faigen
Merck & Co and
Schering-Plough have agreed to pay the $5.4 million in legal costs incurred by 35 states and the District of Columbia regarding their probe into whether the companies violated state consumer protection laws through their use of the ENHANCE trial to market Vytorin (ezetimibe...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Merck & Co to settle Canadian Vioxx claims
- Teva in US agrees to 2017 for Vytorin generic, as Merck has other pending cases
- FDA panel backs Merck's Vytorin in predialysis CKD, but rejects dialysis use
- GBA to decide on future of Merck's ezetimibe after German assessment sees no benefit
ANALYSIS
Other Informa Analysis
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
